EL PASO, Texas – Researchers at The University of Texas at El Paso have identified a novel pharmaceutical compound that successfully kills leukemia and lymphoma cancer cells, potentially paving the way for new forms of therapy. Renato Aguilera, Ph.D., a professor in the Department of Biological Sciences, is the principal...
Latest News
Houston, TX – A medication that appeared to stabilize the function and shape of red blood cells in an earlier study for patients with sickle cell disease is now part of a Phase III clinical trial that is open for enrollment at UTHealth Houston. The trial, led locally by Modupe Idowu,...
Houston, Texas – A four-year, $3.4 million grant to investigate molecular mechanisms and therapeutic treatments for acute respiratory distress syndrome (ARDS) has been awarded to UTHealth Houston researchers by the National Heart, Lung, and Blood Institute, part of the National Institutes of Health. The study led by principal investigators Holger Eltzschig,...
HOUSTON, TX – The body’s immune response to Epstein-Barr virus (EBV) may play a role in causing damage in people with multiple sclerosis, according to a new study led by UTHealth Houston. EBV infection has long been associated with multiple sclerosis, but how the infection might contribute to multiple sclerosis...
Munich, Germany – A team from the Technical University of Munich (TUM) has decoded the factor that makes T cell lymphomas grow comparatively rapidly: A missing “emergency shut-off switch” results in the lymphomas processing particularly large amounts of sugar and triggers other processes as well. Medications for other types of...
San Antonio — Two of the world’s leading Alzheimer’s researchers have co-edited a book critically synthesizing the major new developments in the diagnosis and treatment of Alzheimer’s disease. Building upon a 2007 Alzheimer’s disease conference held in Chile, George Perry, dean of the College of Sciences at The University of...
San Antonio, TX – Karl Klose, director of The South Texas Center for Emerging Infectious Diseases (STCEID) and the Robert J. Kleberg, Jr. and Helen C. Kleberg College of Sciences Endowed Professor, coauthored a research article with Cameron Lloyd ’23, a UTSA doctoral student who graduated in August with a Ph.D. in...
NEWARK, Delaware — Uvax Bio, LLC, a privately held, clinical-stage vaccine company utilizing rational and computational biology to design and deliver novel 1c-SApNP® protein-based vaccines, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating the Company’s HIV-1 vaccine candidates, UVAX-1107 and UVAX-1197, in healthy...
Aurora, Colorado – University of Colorado Cancer Center member Sana Karam, MD, PhD, has received a translational research grant from the V Foundation for Cancer Research, co-founded by ESPN and legendary basketball coach Jim Valvano, to study a new therapeutic that may help pancreatic cancer patients overcome resistance to radiation therapy. “Pancreatic cancer is deadly....
Tallinn, Estonia – The chikungunya virus is widespread in tropical regions, where it is spread to humans by mosquitoes of the genus Aedes. Chikungunya is characterised by high fever, headache, muscle and joint pain, rash and sometimes diarrhoea. This viral disease has become a global health threat. At least five...